Scanning the horizon for high value-add manufacturing science: Accelerating manufacturing readiness for the next generation of disruptive, high-value curative cell therapeutics
posted on 2018-01-18, 11:58authored byPaul C. Hourd, David Williams
Since the Regenerative Medicine sector entered the second phase of its development (RegenMed 2.0) more than a decade ago, there is increasing recognition that current technology innovation trajectories will drive the next translational phase towards the production of disruptive, high value curative cell and gene based regenerative medicines. In this short report, a long lens look within the pluripotent stem cell therapeutic space, both embryonic and induced, is used to gain early insights on where critical technology and manufacturing challenges may emerge. The report offers a future perspective on the development and innovation that will be needed within manufacturing science to add value in the production and commercialisation of the next generation of advanced cell therapies and precision medicines.
Funding
The work described in this article was supported by the UK Regenerative Medicine Platform as part of the work of the Pluripotent Stem Cell Platform (Award MR/L012537/1) focussed on horizon scanning with respect to manufacturing.
History
School
Mechanical, Electrical and Manufacturing Engineering
Published in
Cytotherapy
Citation
HOURD, P.C. and WILLIAMS, D.J., 2018. Scanning the horizon for high value-add manufacturing science: Accelerating manufacturing readiness for the next generation of disruptive, high-value curative cell therapeutics. Cytotherapy, 20 (5), pp.759-767.
This work is made available according to the conditions of the Creative Commons Attribution 4.0 International (CC BY4.0) licence. Full details of this licence are available at: https://creativecommons.org/licenses/by/4.0/
Acceptance date
2018-01-12
Publication date
2018-04-16
Notes
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)